| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
In This Issue...
The demand for drugs to treat osteoporosis will grow substantially during the
next ten years. This growth will be driven by increasing market penetration
facilitated by better diagnosis of the disease, the large aging population,
and increasing treatment of male osteoporosis. A further stimulus to growth
will be the availability of new agents. In this report, we provide an overview
of osteoporosis, including its etiology and its worldwide prevalence. We
discuss marketed treatments for the disease and present an outline of the
current market and major players. The report also identifies the most
promising drugs in development for the treatment of osteoporosis, including
agents in currently marketed drug classes and those representing novel
approaches to osteoporosis treatment. Finally, we forecast sales of
osteoporosis agents through 2009, identifying the drugs most likely to have a
significant impact and discussing potential threats from generic agents.
TABLE OF CONTENTS
Introduction
The Disease
- Causes of Osteoporosis
- Disease Prevalence
Current Treatments
- Bisphosphonates
- Selective Estrogen Receptor Modulators
- Parathyroid Hormone Agonists
- Calcitonin
- Vitamin D and Vitamin D Analogues
- Hormone Replacement Therapy
- Other Treatments
Current Market
New Treatments
- Emerging Agents in Currently Marketed Drug Classes
- New Drug Classes
Market Outlook
- Generic Drug Threats
- Osteoporosis Market
- Through 2009
|
